| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.57 M USD | -8.64 M USD | -14.12 M USD | -10.26 M USD | -10.13 M USD | -9.11 M USD | -6.43 M USD | -9.35 M USD | -4.68 M USD | -7.17 M USD | -9.06 M USD | -14.52 M USD |
| Depreciation & Amortization | 319000 USD | 842000 USD | 907000 USD | 335000 USD | 185000 USD | 78000 USD | 102000 USD | 105000 USD | 578000 USD | 1.44 M USD | 1.65 M USD | 1.84 M USD |
| Stock-Based Compensation | 1.39 M USD | 82000 USD | 291000 USD | 369000 USD | 309000 USD | 45000 USD | 2000 USD | 42000 USD | 219000 USD | 273000 USD | 911000 USD | 10.22 M USD |
| Capital Expenditures | 185000 USD | 690000 USD | 530000 USD | 1.41 M USD | 3.74 M USD | 360000 USD | 147000 USD | 11000 USD | 1.19 M USD | 671000 USD | 695000 USD | 2.17 M USD |
| Cash Flow from Investing | 913000 USD | -194000 USD | -501000 USD | -1.10 M USD | -1.65 M USD | 1.75 M USD | 1.38 M USD | -145000 USD | -1.14 M USD | -617000 USD | -658000 USD | -1.74 M USD |
| Cash Flow from Financing | 8.20 M USD | 9.09 M USD | 11.71 M USD | 3.34 M USD | 705000 USD | 30.93 M USD | 1.39 M USD | 14.40 M USD | -559000 USD | 3.22 M USD | 2.96 M USD | 32.23 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | 133000 USD | — | — | — | — | — | — | — | — | — | 120000 USD | — |
| Free Cash Flow | -8.76 M USD | -9.33 M USD | -14.64 M USD | -11.67 M USD | -13.87 M USD | -9.47 M USD | -6.58 M USD | -9.36 M USD | -5.87 M USD | -7.84 M USD | -9.76 M USD | -16.69 M USD |
Sintx Technologies Inc. is an advanced ceramics company specializing in the research, development, and commercialization of silicon nitride-based medical devices and biomaterials. It manufactures solid and porous silicon nitride products, silicon nitride powder, coatings, and composite materials including polyether ether ketone and polyetherketoneketone for biomedical, technical, and antipathogenic applications. The company offers innovative solutions such as the FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System and OsseoSculpt biologic, which feature pro-osteogenic, bacteriostatic, and enhanced imaging properties. Sintx Technologies Inc. also develops antipathogenic fibrous materials and fabrics for medical textiles, wound dressings, filtration, PPE, and high-touch surfaces, supported by composition and method patents. Recent advancements include the SiN/PEEK compound produced via partnerships for AI-assisted, 3D-printed patient-specific implants targeting orthopedic, spine, and reconstructive surgery markets. Founded in 1996 and headquartered in Salt Lake City, Utah, Sintx Technologies Inc. focuses on infection-resistant devices, polymer composites, and licensing opportunities in the medical device sector.